AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

4,551.00GBp
4:43am EDT
Price Change (% chg)

-26.50p (-0.58%)
Prev Close
4,577.50p
Open
4,596.50p
Day's High
4,600.00p
Day's Low
4,549.00p
Volume
177,184
Avg. Vol
2,153,559
52-wk High
4,946.41p
52-wk Low
3,085.21p

AZN.L

Chart for AZN.L

About

AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. AstraZeneca discovers, develops and commercializes prescription medicines for six areas of healthcare: Cardiovascular, Gastrointestinal, Infection, Neuroscience, Oncology, and Respiratory and Inflammation. It has a range of medicines that includes treatments... (more)

Overall

Beta: 0.38
Market Cap (Mil.): £57,760.46
Shares Outstanding (Mil.): 1,262.59
Dividend: 53.10
Yield (%): 3.71

Financials

  AZN.L Industry Sector
P/E (TTM): 47.36 32.30 33.23
EPS (TTM): 0.97 -- --
ROI: 5.03 17.96 17.21
ROE: 8.94 18.60 18.01
Search Stocks

Astra heart pill safe to use in ambulance but no extra benefit

BARCELONA, Sept 1 - AstraZeneca's blood-thinning drug Brilinta is safe to use in the ambulance when heart attack patients are being rushed to hospital but giving it early in this way does not provide any extra benefit.

01 Sep 2014

FTSE inches higher, Tesco slumps after profit warning

LONDON, Aug 29 - Britain's top share index ended slightly higher on Friday, with stronger pharmaceutical stocks on renewed merger and acquisition talks outpacing a sharp decline in retail stocks after another profit warning by Tesco .

29 Aug 2014

FTSE steadies, Tesco slumps after profit warning

LONDON, Aug 29 - Britain's top share index steadied in cautious trading on Friday, with stronger pharmaceutical stocks on renewed merger and acquisition talks offsetting weaker retailers after another profit warning by Tesco.

29 Aug 2014

FTSE edges higher, stronger drugmakers outpace weak retailers

LONDON, Aug 29 - Britain's top share index edged higher in cautious trading on Friday, with stronger pharmaceutical stocks on renewed merger and acquisition talks outpacing weaker retailers after another profit warning by Tesco .

29 Aug 2014

AstraZeneca boosted by start of new cancer drug trial

LONDON - Hopes for AstraZeneca's promising cancer drug pipeline were boosted on Friday by news the company had moved its immuno-oncology medicine MEDI-4736 into a mid-stage study in colorectal cancer.

29 Aug 2014

UPDATE 1-AstraZeneca boosted by start of new cancer drug trial

* AstraZeneca shares up 2 percent (Adds sales forecasts, detail on competitors, latest shares)

29 Aug 2014

Hopes rise for AstraZeneca cancer drug with start of new trial

LONDON, Aug 29 - Hopes for AstraZeneca's promising cancer drug pipeline were boosted on Friday by news the company had moved its immuno-oncology medicine MEDI-4736 into a mid-stage study in colorectal cancer.

29 Aug 2014

Roche to buy U.S. biotech firm InterMune for $8.3 billion

LONDON/ZURICH - Roche Holding AG has agreed to buy U.S. biotech company InterMune Inc for $8.3 billion in cash, marking the latest multibillion-dollar deal in a consolidating pharmaceutical sector.

24 Aug 2014

UPDATE 3-Roche to buy U.S. biotech firm InterMune for $8.3 bln

* Consensus 2019 sales for InterMune lung drug $1.04 bln (Adds comments from Roche CEO, analyst)

24 Aug 2014

Lilly psoriasis drug impresses; battle nears with Amgen, Novartis

- An experimental new psoriasis treatment from Eli Lilly and Co proved superior to Amgen Inc's blockbuster Enbrel, drawing it closer to a potential marketing battle with new products being developed by Amgen and Novartis AG.

21 Aug 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: New Constructs, LLC
$25.00
Provider: S&P Capital IQ – STARS Reports
$127.00
Provider: Reuters Investment Profile
$20.00
Provider: Pechala's Reports
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks